Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on brain-targeted therapeutics, has announced significant updates on its Phase IIa feasibility trial of ONP-002, a potential treatment for mild traumatic brain injury (mTBI), commonly known as concussion. The company has dosed nine participants across three active clinical sites in Australia—Alfred Health, Mackay, and Royal Adelaide Hospital—and has received responses from the U.S. Food and Drug Administration (FDA) regarding its Type B meeting request briefing package submitted in July 2026.
The FDA's responses are a critical step in Oragenics' regulatory pathway. The company is currently reviewing the feedback and remains focused on submitting an Investigational New Drug (IND) application by the end of 2026. This submission is essential for initiating clinical trials in the United States, which would follow the ongoing Australian studies. The intranasal delivery platform used for ONP-002 is designed to target the brain directly, potentially offering a first-in-class treatment for concussion, a condition with limited therapeutic options.
In addition to regulatory progress, Oragenics disclosed receiving a deficiency letter from the NYSE American on August 26, 2026, related to stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company has 45 days from receipt of the letter to submit a plan to regain compliance. Oragenics intends to do so within the required timeframe. If the plan is accepted, the company would be able to maintain its listing during a cure period, subject to periodic review, with a compliance deadline of February 25, 2028. This development is important for shareholders as it affects the company's listing status and market confidence.
The advancement of ONP-002 through clinical trials is a pivotal moment for Oragenics, as mTBI affects millions worldwide, often leading to long-term cognitive and neurological issues. Current treatments are limited to symptom management, leaving a significant unmet medical need. Oragenics' proprietary intranasal delivery technology, which bypasses the blood-brain barrier, holds promise not only for concussion but also for other neurological conditions such as Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. The success of ONP-002 could pave the way for a new class of brain-targeted therapies.
Investors and stakeholders are closely watching these developments, as the company navigates both clinical progress and regulatory compliance. The FDA's feedback and the planned IND submission are critical milestones that could accelerate the path to U.S. trials. Meanwhile, addressing the NYSE American listing requirements is essential to maintain investor confidence and access to capital markets.
Oragenics' commitment to addressing significant unmet needs in neurological care is evident in its strategic focus on brain-targeted therapeutics. The ongoing Phase IIa trial in Australia is designed to assess the feasibility and safety of ONP-002, providing essential data to support further clinical development. The company's collaboration with multiple clinical sites enhances the robustness of the trial, and the responses from the FDA will help refine its regulatory strategy.
For more information on Oragenics and its pipeline, visit the company's newsroom at https://nnw.fm/OGEN. The full press release can be accessed at https://nnw.fm/HZ5fb.
